UiPath (NYSE:PATH) Price Target Increased to $15.00 by Analysts at Barclays

UiPath (NYSE:PATH) had its target price hoisted by stock analysts at Barclays from $14.00 to $15.00 in a report released on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the healthcare company’s stock. Barclays‘s target price would suggest a potential upside of 15.92% from the stock’s current price.

Several other research firms have also recently commented on PATH. KeyCorp reissued a “sector weight” rating on shares of UiPath in a report on Thursday, May 30th. Wells Fargo & Company boosted their price target on UiPath from $14.00 to $15.00 and gave the stock an “equal weight” rating in a report on Friday. Macquarie downgraded UiPath from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $29.00 to $12.00 in a research report on Monday, June 3rd. Evercore ISI boosted their price target on UiPath from $13.00 to $16.00 and gave the company an “in-line” rating in a research report on Friday. Finally, TD Cowen reissued a “hold” rating and set a $17.00 price target (down previously from $28.00) on shares of UiPath in a research report on Thursday, May 30th. Sixteen investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, UiPath currently has a consensus rating of “Hold” and an average price target of $17.65.

UiPath Stock Up 1.6 %

NYSE:PATH traded up $0.20 on Friday, reaching $12.94. The company’s stock had a trading volume of 5,052,699 shares, compared to its average volume of 9,851,714. The firm has a market cap of $7.41 billion, a price-to-earnings ratio of -83.06 and a beta of 0.87. UiPath has a 12-month low of $10.37 and a 12-month high of $27.87. The stock has a 50 day moving average price of $12.22 and a 200 day moving average price of $16.80.

UiPath (NYSE:PATH) last released its quarterly earnings data on Thursday, September 5th. The healthcare company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.01. The business had revenue of $316.00 million during the quarter, compared to analysts’ expectations of $303.69 million. UiPath had a negative return on equity of 2.97% and a negative net margin of 6.41%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.09) EPS. Equities research analysts expect that UiPath will post -0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On UiPath

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC bought a new stake in UiPath during the 2nd quarter worth about $155,000. Advisory Alpha LLC acquired a new position in shares of UiPath during the 2nd quarter worth about $131,000. Capital Impact Advisors LLC increased its stake in shares of UiPath by 162.9% during the 2nd quarter. Capital Impact Advisors LLC now owns 36,400 shares of the healthcare company’s stock worth $462,000 after purchasing an additional 22,553 shares during the last quarter. Sunbelt Securities Inc. increased its stake in shares of UiPath by 15.4% during the 2nd quarter. Sunbelt Securities Inc. now owns 20,970 shares of the healthcare company’s stock worth $266,000 after purchasing an additional 2,792 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of UiPath by 2,495.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 682,078 shares of the healthcare company’s stock worth $8,649,000 after purchasing an additional 655,798 shares during the last quarter. 62.50% of the stock is owned by institutional investors.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.